Table 2.
Clinical and immunological characteristics of SLE-related APS patients and SLE-"aPL carriers"
| SLE-APS | SLE-"aPL carriers" | |
|---|---|---|
| Total patients | 6 | 7 |
| Female–male sex | 6–0 | 7–0 |
| Age (years, mean ± SD) | 53 ± 12 | 46 ± 12 |
| Disease duration (years, mean ± SD) | 18 ± 15 | 15 ± 11 |
| Remission (SLEDAI < 2) | 6 | 7 |
| Active disease (SLEDAI > 2) | 0 | 0 |
| Clinical domains | ||
| Cutaneous domain | 5 | 7 |
| Arthritis domain | 1 | 2 |
| Neurological domain | 1 | 0 |
| Serositis domain | 1 | 1 |
| Hematologic domain | 1 | 3 |
| Renal domain | 0 | 1 |
| Current therapy | ||
| Glucocorticoids (prednisone ≤ 5 mg per day) | 5 | 7 |
| Hydroxychloroquine | 2 | 5 |
| cDMARDs (methotrexate, azathioprine, mycophenolate mofetil) | 4 | 4 |
SLE systemic lupus erythematosus, SLEDAI systemic lupus erythematosus disease activity index, APS antiphospholipid syndrome, aPL antiphospholipid antibodies, SD standard deviation, cDMARDs conventional disease-modifying anti-rheumatic drugs